-
【Nature】The weakness of the new crown virus has been found! Boston University and Harvard Medical School open new ways to eliminate COVID
Time of Update: 2023-02-01
Referrals, live broadcasts/events01/12 14:00-16:00 OnlineOlink Multiomics Cohort ForumScan the code to participate for free03/02-03 09:00-18:00 ShanghaiThe 2nd Yangtze River Delta Single-cell Omics Technology Application ForumScan the code to participate for freeThis article is the original of Translational Medicine Network, please indicate the source for reprintingWritten by JevinThe new coronavirus usually infects humans through the respiratory tract and causes damage to the respiratory system and various organs of the human body.
-
Professor Huang Wenrong: Progress in first-line induction and consolidation therapy for primary central nervous system lymphoma The 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Professor Huang Wenrong said that previous prospective studies have proved that ASCT and whole-brain radiotherapy can significantly improve the median progression-free survival (PFS) of patients with first-line therapy remission of PCNSL compared with non-myeloablative high-dose consolidation chemotherapy.
-
Professor Huang Wenrong: Progress in first-line induction and consolidation therapy for primary central nervous system lymphoma The 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Professor Huang Wenrong said that previous prospective studies have proved that ASCT and whole-brain radiotherapy can significantly improve the median progression-free survival (PFS) of patients with first-line therapy remission of PCNSL compared with non-myeloablative high-dose consolidation chemotherapy.
-
Strength rating of Chinese pharmaceutical universities
Time of Update: 2022-11-26
01 Rating of pharmaceutical strength of Chinese universities01 Rating of pharmaceutical strength of Chinese universitiesThe 2022 Medical Strength Selection (see the end of the article for the results)
-
The EU CHMP recommends approval of Beyfortus (nirsevimab) for the prevention of RSV disease in infants
Time of Update: 2022-10-03
*For medical professionals only▶ The EU CHMP recommends approval of Beyfortus (nirsevimab) for the prevention of RSV disease in infants· The approval opinion is based on the results of Beyfortus clin
-
At the moment of the epidemic, SABIC assists the production of anti-epidemic materials such as masks, medical equipment, and liquid outer packaging
Time of Update: 2022-08-22
These medical protective products have become the primary guarantee to fight the epidemic, and medical equipment such as ventilators and monitors are important materials that are related to life safety The global spread of the new crown epidemic, masks, gloves, disinfection supplies.
-
There are new regulations on the amount of centralized procurement, and the non-selected varieties have a new chance
Time of Update: 2022-06-09
Too few reports, resulting in the actual use of medical institutions exceeding 200% or even 400% of the predicted purchases At the end of June 2021, the Yunnan Provincial Drug Collection Platform showed that acarbose, amoxicillin granules, metformin hydrochloride sustained-release tablets and other varieties increased the declaration work of national drug supplement supply enterprises .
-
Another pharmaceutical company showed its 2021 transcript, and its total revenue and R&D investment doubled
Time of Update: 2022-05-01
Excluding upfront payments for newly signed license agreements, core R&D spending in 2021 was $252 million compared to $139.
It will continue to invest in R&D and advance its in-house pipeline with global rights to achieve its mission of benefiting patients around the world .
-
Spotlight 2022 JP Morgan Conference Illumina Announces Technology Updates and Multiple Collaborations
Time of Update: 2022-01-22
Illumina is leading the $14 billion market for therapy options, deSouza said, highlighting 11 partnerships for TruSight comprehensive oncology assays, including the just-announced partnership with Boehringer Ingelheim, and 34 IVD development partnerships , including a partnership with Agendia announced this week .
-
The State Food and Drug Administration cancels the registration certificate of disposable infusion set with needle medical device
Time of Update: 2022-01-12
On December 1, the State Food and Drug Administration issued an announcement stating that, in accordance with the Regulations on the Supervision and Administration of Medical Devices, the medical devi
-
Children's HIV use dolutegravire antiretroviral drug effect is significant
Time of Update: 2022-01-09
The study, published today in The New England Journal of Medicine, found that compared with standard therapies, dolutegravire-based treatment options have been widely used in adults, reducing 3-18 years of age The chance of treatment failure in young people is about 40% .
-
Professor Huang Jing: O+ chemotherapy and O+Y each show "food" power, CheckMate-648 sets two new standards for the first-line esophageal squamous cell carcinoma
Time of Update: 2021-10-11
Professor Huang Jing pointed out that in the first-line treatment of advanced esophageal squamous cell carcinoma based on immune checkpoint inhibitors, CheckMate-648 is by far the largest randomized, global phase III study, including China and other countries from all over the world.
-
The fifth batch of supplementary documents issued by Guocai Shanghai
Time of Update: 2021-06-17
The unselected highest-priced drugs of the same species that meet the requirements of this centralized procurement declaration can continue to be purchased and used after a gradual price reduction (based on the selected price) according to the price difference.
-
Document issued in one place: Gene sequencer speeds up import restrictions
Time of Update: 2021-06-03
Comparing the list of imported products released by Guangdong Province in recent years, it can be found that the 86 types of medical equipment that have been reduced this year, including gene sequencers, have released signals that the field of genetic testing is expected to accelerate the realization of import substitution.
-
The results of the first phase 3 study of the first-line immunotherapy for gastric cancer in China are announced, which is expected to revolutionize the treatment landscape
Time of Update: 2021-04-18
"The Bristol-Myers Squibb Company press release pointed out that in the clinical study of immunotherapy for gastric cancer and gastroesophageal junction cancer covering patients in mainland China, the CheckMate-649 study is the first and currently the only phase 3 study of first-line treatment with positive results.
